Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Truist Bank AS Administrative Agent currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio shows a concentrated prosecution strategy, as all pending actions are assigned to 1 distinct examiner and 1 distinct art unit. This concentration suggests that the current legal challenges for Truist Bank AS Administrative Agent are confined to a specific niche of pharmaceutical or biological examination.
The primary point of contact for these matters is GHALI, ISIS A D, who serves as the busiest examiner for the portfolio. GHALI, ISIS A D is responsible for 2 busiest examiner pending actions, which accounts for the entirety of the current workload in this sector. For a practitioner, this means that the outcome of the entire pending portfolio depends on the decisions of an individual within an art unit.
The lack of diversity in examiners and art units simplifies the logistical aspect of prosecution. Because there is 1 distinct examiner involved, the prosecution team can focus their efforts on understanding the specific requirements and historical patterns of GHALI, ISIS A D. This focused approach is critical when dealing with the pending office actions currently on the docket.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GHALI, ISIS A D | 2 | 27.9% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16678466 | INHALABLE HEMODYNAMIC AGENTS AND METHODS OF USING THE SAME | GHALI, ISIS A D | 42d overdue |
| 16130325 | SAFER AND MORE EFFECTIVE METHODS OF TRANSMUCOSAL DELIVERY FOR RAISING BLOOD PRESSURE AND STIMULATING THE BODY | GHALI, ISIS A D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16678466 | INHALABLE HEMODYNAMIC AGENTS AND METHODS OF USING THE SAME | GHALI, ISIS A D | 42d overdue |
| 16130325 | SAFER AND MORE EFFECTIVE METHODS OF TRANSMUCOSAL DELIVERY FOR RAISING BLOOD PRESSURE AND STIMULATING THE BODY | GHALI, ISIS A D | — |
| Art Unit | Apps |
|---|---|
| 1611 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16678466 | INHALABLE HEMODYNAMIC AGENTS AND METHODS OF USING THE SAME | GHALI, ISIS A D | 1611 | §103§112 | Non-Final OA | 42d overdue | Pending | Nov 08, 2019 |
| 16130325 | SAFER AND MORE EFFECTIVE METHODS OF TRANSMUCOSAL DELIVERY FOR RAISING BLOOD PRESSURE AND STIMULATING THE BODY | GHALI, ISIS A D | 1611 | §103 | Non-Final OA | — | Pending | Sep 13, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial